COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03250377
Recruitment Status : Enrolling by invitation
First Posted : August 15, 2017
Last Update Posted : August 7, 2020
Information provided by (Responsible Party):
UCB Pharma ( UCB Biopharma S.P.R.L. )

No Study Results Posted on for this Study
Recruitment Status : Enrolling by invitation
Estimated Primary Completion Date : February 2025
Estimated Study Completion Date : February 2025